Zobrazeno 1 - 7
of 7
pro vyhledávání: '"I V Chernokhaeva"'
Autor:
P K Yablonskiy, T I Vinogradova, Yu N Levashev, M V Pavlova, E K Zilber, A A Starshinova, N V Sapozhnikova, I V Chernokhaeva, L I Archakova, N V Zabolotnykh, M L Vitovskaya
Publikováno v:
Терапевтический архив, Vol 88, Iss 3, Pp 111-115 (2016)
The paper sets forth the stages of design and introduction of the new Russian tuberculosis (TB) drug perchlozon registered in the Russian Federation in 2012. Based on the results of Phases I-III clinical trials, the authors evaluate the efficacy and
Externí odkaz:
https://doaj.org/article/fb038c632bd145359e573e43d0d89e97
Autor:
M. А. Belokurov, A. А. Starshinova, V. Yu. Zhuravlev, L. D. Kiruchina, М. V. Pavlova, I. V. Chernokhaeva, L. I. Archakova, A. R. Kozak, V. A. Tsinzerling, P. K. Yablonskii
Publikováno v:
Журнал инфектологии, Vol 7, Iss 2, Pp 98-104 (2015)
Differential diagnosis disseminated diseases provides sarcoidosis and tuberculosis. Frequency of mistakes consists over 40% [Visel AA, 2013]. That’s why including of new diagnosis methods is weary important. Оbjective: to indicat diagnosis value o
Externí odkaz:
https://doaj.org/article/df17eb8580fb4ceda48358021c9d5c99
Autor:
M. V. Pavlova, I. V. Chernokhaeva, A. A. Starshinova, N. V. Sapozhnikova, E. N. Belyaeva, A. L. Chuzhov
Publikováno v:
Tuberkulez i Bolezni Lëgkih, Vol 94, Iss 8, Pp 23-29 (2016)
The article describes the study of comparative efficiency of fenazid (isonicotinoilhydrazine-О,N’) ferrous dihydrate sulphate (II) and isoniazid in drug susceptible pulmonary tuberculosis patients.The high treatment efficiency namely significant i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6017299fb389c1877e0ce499b4d78c42
https://www.tibl-journal.com/jour/article/view/913
https://www.tibl-journal.com/jour/article/view/913
Autor:
M. V. Pavlova, M. A. Belokurov, I. V. Chernokhaeva, O. A. Yakunova, A. R. Kozak, V. A. Tsinzerling
Publikováno v:
Tuberkulez i Bolezni Lëgkih, Vol 94, Iss 3, Pp 57-61 (2016)
TB doctors and pulmonologists are very well familiar with the issue of differential diagnostics between pulmonary tuberculosis and sarcoidosis. Despite the introduction of new diagnostic tools for disseminated diseases, the absence of pathognomonic,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::0bd92d15964dbe34ba5027226b2f534c
https://www.tibl-journal.com/jour/article/view/860
https://www.tibl-journal.com/jour/article/view/860
Autor:
M. V. Pavlova, A. A. Starshinova, N. V. Sapozhnikova, I. V. Chernokhaeva, L. I. Archakova, P. K. Yablonskiy
Publikováno v:
Tuberkulez i Bolezni Lëgkih, Vol 0, Iss 12, Pp 61-67 (2015)
Treatment of multiple drug resistant tuberculosis presents a serious challenge. Use of perchlozon (thioureidoiminomethylpyridini um) in the combination with the other five anti-tuberculosis drugs during 6 months of treatment allowed achieving cessati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::7c02b10e7f2ebdfd5a648bea2069317d
https://www.tibl-journal.com/jour/article/view/832
https://www.tibl-journal.com/jour/article/view/832
Publikováno v:
Tuberkulez i Bolezni Lëgkih, Vol 0, Iss 1, Pp 10-14 (2015)
adolescents. Fluorography is the basic method used as usual to detect tuberculosis in adolescents. The use of diaskintest in the diagnosis of tuberculosis infection in adolescents has reinforced its high informative value. The test was positive in 96
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::ae5ac663f0cb17b1ca96534ac6d3fefd
https://www.tibl-journal.com/jour/article/view/324
https://www.tibl-journal.com/jour/article/view/324
Autor:
T. I. Vinogradova, N. V. Sapozhnikova, Yu. N. Levashev, Piotr Yablonskiy, I. V. Chernokhaeva, M. L. Vitovskaya, N. V. Zabolotnykh, Pavlova Mv, A. A. Starshinova, E. K. Zilber, Ludmila Archakova
Publikováno v:
Терапевтический архив, Vol 88, Iss 3, Pp 111-115 (2016)
ResearcherID
ResearcherID
The paper sets forth the stages of design and introduction of the new Russian tuberculosis (TB) drug perchlozon registered in the Russian Federation in 2012. Based on the results of Phases I-III clinical trials, the authors evaluate the efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df454b8bf06694dd21f4435b16c4b522
https://doi.org/10.17116/terarkh2016883111-115
https://doi.org/10.17116/terarkh2016883111-115